Records containing: Recurrent Childhood Soft Tissue Sarcoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-24A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications
-
CLINICAL_TRIALS study record update · 2025-07-11Adopting a Functional Precision Medicine Approach For Individualized Pediatric Cancer Treatments
-
CLINICAL_TRIALS study record update · 2024-09-19NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations
-
CLINICAL_TRIALS study record update · 2024-04-25NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes
-
CLINICAL_TRIALS study record update · 2023-10-03A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2023-05-10Personalized Ex Vivo Drug Screening and Genomics Profiling to Guide Individualized Treatments for Children With Relapsed or Refractory Solid Tumors and Leukemias
-
CLINICAL_TRIALS study record update · 2017-06-05A Phase II Study of MLN8237, a Selective Aurora A Kinase Inhibitor in Children With Recurrent/Refractory Solid Tumors and Leukemias
-
CLINICAL_TRIALS study record update · 2016-05-17Observational - Potentially Actionable Mutations in Archived Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)
-
CLINICAL_TRIALS study record update · 2016-05-17A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma
-
CLINICAL_TRIALS study record update · 2015-07-27Trabectedin and Irinotecan in Pediatric Refractory Sarcomas
-
CLINICAL_TRIALS study record update · 2015-04-15A Phase II Study of Gleevec (Imatinib Mesylate, NSC 716051 Formerly STI571) in Children With Refractory or Relapsed Solid Tumors
-
CLINICAL_TRIALS study record update · 2015-03-31A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
-
CLINICAL_TRIALS study record update · 2015-03-30A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors
-
CLINICAL_TRIALS study record update · 2014-11-14Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors
-
CLINICAL_TRIALS study record update · 2014-01-27A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcomas
-
CLINICAL_TRIALS study record update · 2013-09-30A Phase I Study of Pazopanib as a Single Agent for Children With Relapsed or Refractory Solid Tumors
-
CLINICAL_TRIALS study record update · 2013-07-02A PHASE I STUDY OF FLAVOPIRIDOL (NSC# 649890; IND# 46211) IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC SOLID TUMORS OR LYMPHOMAS
-
CLINICAL_TRIALS study record update · 2013-06-05A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors
-
CLINICAL_TRIALS study record update · 2013-06-05A Phase I Study of Single Agent OSI-774 (Tarceva) (NSC# 718781, IND# 63383) Followed by OSI-774 With Temozolomide for Patients With Selected Recurrent/Refractory Solid Tumors, Including Brain Tumors
-
CLINICAL_TRIALS study record update · 2013-06-05A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas
-
CLINICAL_TRIALS study record update · 2013-06-04A Multicenter Phase I Trial of 17-N-allylamino-17-demethoxy Geldanamycin (17-AAG, NSC #330507) in Patients With Recurrent/Refractory Pediatric Solid Tumors (Ewing's Sarcoma, Desmoplastic Small Round Cell Tumor, Osteosarcoma, Neuroblastoma, and Rhabdomyosarcoma) and Leukemia